← Leaderboards
Jennifer S Guimbellot
University Of Alabama At Birmingham
$2,518,311
Attributed
$2,866,434
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.3M · FY2006–25$2M$1.5M$1M$500K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$2,866,434 · 4
By mechanism
R01$1,931,052 · 2
K23$838,620 · 1
F30$96,762 · 1
Top collaborators
- Rachel G Sinkey1 shared
Most similar at University Of Alabama At Birmingham
Same institution · by research overlap
- Steven Mark Rowe$18,443,646
- Barry P Sleckman$19,849,738
- Dwight J Rouse$18,107,824
- Alan Thevenet N. Tita$31,628,801
- David W Kimberlin$10,865,588
Others in their field
Top investigators on “Cystic Fibrosis Transmembrane Conductance Regulator”
- John F Engelhardt · University Of Iowa$19,572,056
- David A Stoltz · University Of Iowa$19,554,520
- Joseph Zabner · University Of Iowa$16,996,052
- Paul B McCray · University Of Iowa$15,787,286
- Garry R Cutting · Johns Hopkins University$14,051,583
- Anjaparavanda P Naren · University Of Tennessee Health Sci Ctr$13,961,163
Research focus
Cystic Fibrosis Transmembrane Conductance RegulatorLungAffectResponseTissuesProteinsVariantDrug KineticsFunctional DisorderPatient CareCaringChloridesPharmaceutical PreparationsCombined Modality TherapyCystic FibrosisFutureMetabolismLifePharmacologyCystic Fibrosis PatientsDependenceDoseEpithelial CellsEnzymes
Grant awards (11)
Evaluating Maternal and Neonatal Pharmacokinetics of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators - The ELECTRA Pregnancy Study$696,246
R01 · FY2025 · HD · contact PI
ENsuring ACcess to optimal Therapy in CF: ENACT study$592,346
R01 · FY2025 · HL · contact PI
ENsuring ACcess to optimal Therapy in CF: ENACT study$642,460
R01 · FY2024 · HL · contact PI
Pharmacometric approaches to precision optimization of ivacaftor response in cystic fibrosis patients$150,012
K23 · FY2024 · HL · contact PI
Pharmacometric approaches to precision optimization of ivacaftor response in cystic fibrosis patients$172,152
K23 · FY2023 · HL · contact PI
Pharmacometric approaches to precision optimization of ivacaftor response in cystic fibrosis patients$172,152
K23 · FY2022 · HL · contact PI
Pharmacometric approaches to precision optimization of ivacaftor response in cystic fibrosis patients$172,152
K23 · FY2021 · HL · contact PI
Pharmacometric approaches to precision optimization of ivacaftor response in cystic fibrosis patients$172,152
K23 · FY2020 · HL · contact PI
Effects of ozone on CFTR expression and HIF signaling$33,051
F30 · FY2008 · ES · contact PI
Effects of ozone on CFTR expression and HIF signaling$33,081
F30 · FY2007 · ES · contact PI
Effects of ozone on CFTR expression and HIF signaling$30,630
F30 · FY2006 · ES · contact PI